Phase I results with ModraDoc006/r published in the European Journal of Cancer
October 15, 2017
14 october 2017
Researchers from the Netherlands Cancer Institute have published results from a Phase I study with oral docetaxel in the European Journal of Cancer, in a paper titled, ‘A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir’.
This is the first publication of safety, tolerability and initial clinical activity data for ModraDoc006/r in patients with metastatic solid tumors.